Open Payments

Boston Medical Center

Type
Teaching hospital
Where
EAST BOSTON, MA
Medicare CCN
220031
Received
$5,070,701 in 469 records, 2021 ($629,092 general, $4,441,608 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment75$629,092
2021Research payment394$4,441,608

By company

CompanyRecordsAmountYears
PFIZER INC.110$2,324,7502021
Merck Sharp & Dohme LLC14$748,3622021
Hoffmann-La Roche Limited9$280,3652021
Gilead Sciences, Inc.2$195,5832021
Regeneron Pharmaceuticals, Inc.2$167,1822021
Alexion Pharmaceuticals, Inc.29$161,9822021
COLOPLAST CORP1$120,0002021
VERTEX PHARMACEUTICALS INCORPORATED4$113,3162021
Abbott Laboratories7$85,8082021
C. R. Bard, Inc. & Subsidiaries3$72,8082021
SANOFI US SERVICES INC.1$70,0002021
Novo Nordisk AS105$60,5252021
Indivior Inc.12$60,0002021
Janssen Research & Development, LLC16$58,2712021
KARL STORZ Endoscopy-America26$54,9932021
Biogen, Inc.1$47,6442021
Laminate Medical Technologies inc.5$44,3792021
Takeda Pharmaceuticals U.S.A., Inc.22$44,2142021
Intercept Pharmaceuticals, Inc.7$35,6362021
Boston Scientific Corporation3$31,6252021
Organon Llc14$30,6632021
ABBVIE INC.5$27,7952021
Celgene Corporation3$27,0662021
GENZYME CORPORATION1$25,0002021
G1 Therapeutics, Inc.2$24,7862021
Akcea Therapeutics, Inc.2$17,3832021
Medline Industries LP4$16,9142021
Rigel Pharmaceuticals, Inc.7$15,3872021
Astute Medical, Inc.1$15,0002021
Becton, Dickinson and Company22$14,9742021
BIOTISSUE HOLDINGS INC.1$12,6752021
E.R. Squibb & Sons, L.L.C.1$10,0312021
AstraZeneca UK Limited2$7,9012021
Incyte Corporation3$7,7292021
Bayer Healthcare Pharmaceuticals Inc.3$7,6032021
KLS-Martin L.P.2$7,5002021
Roche Diagnostics Operations, Inc.3$5,7402021
Richard Wolf Medical Instruments Corp.1$3,8172021
ROCHE MOLECULAR SYSTEMS, INC.2$3,7832021
Neurocrine BioSciences, Inc.2$2,6002021
Acrotech Biopharma Inc.1$2,4272021
GLOBAL BLOOD THERAPEUTICS, INC.1$1,9112021
Genentech, Inc.1$1,3002021
Allergan, Inc.1$1,2002021
GE HEALTHCARE1$6992021
Conformis, Inc.1$6502021
Bio-Rad Laboratories, Inc.1$5912021
Johnson & Johnson Health Care Systems Inc.2$1202021

By nature of payment

NatureRecordsAmount
Research payment394$4,441,608
Grant7$333,896
Charitable Contribution24$159,974
Compensation for services other than consulting, including serving as faculty or as a speaker at a v12$60,000
Education27$55,692
Royalty or License1$15,000
Long term medical supply or device loan1$3,817
Debt forgiveness3$711

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Merck Sharp & Dohme LLC$198,568Research paymentIn-kind items and servicesCharacterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select2021
2021-12-31Gilead Sciences, Inc.$70,583GrantCash or cash equivalent2021
2021-12-31Merck Sharp & Dohme LLC$39,090Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2021
2021-12-31Merck Sharp & Dohme LLC$23,854Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEAn Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon2021
2021-12-31Merck Sharp & Dohme LLC$20,831Research paymentIn-kind items and servicesIMPLANON Drug, WOMENS HEALTHA Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK2021
2021-12-31Merck Sharp & Dohme LLC$13,778Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2021
2021-12-31KARL STORZ Endoscopy-America$13,059EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$6,408EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$3,638EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$3,016EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$2,994EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$2,876EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31Merck Sharp & Dohme LLC$2,779Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2021
2021-12-31KARL STORZ Endoscopy-America$2,773EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31Merck Sharp & Dohme LLC$2,650Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U2021
2021-12-31KARL STORZ Endoscopy-America$2,183EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$2,073EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$2,029EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$2,022EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$1,852EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$1,660EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$1,660EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31AstraZeneca UK Limited$1,652Research paymentIn-kind items and servicesSAPHNELO Biological, Inflammation and AutoimmunitySafety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Ne2021
2021-12-31KARL STORZ Endoscopy-America$1,547EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31Roche Diagnostics Operations, Inc.$1,527Research paymentCash or cash equivalentcobas c 311 Device, Core LabCIMRD0014692021
2021-12-31KARL STORZ Endoscopy-America$1,411EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$872EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$872EducationIn-kind items and services Device, LAPAROSCOPY2021
2021-12-31KARL STORZ Endoscopy-America$814EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$490EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31ABBVIE INC.$442Research paymentIn-kind items and servicesA Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in2021
2021-12-31KARL STORZ Endoscopy-America$281EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$189EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$125EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$57EducationIn-kind items and services Device, LAPAROSCOPY2021
2021-12-31KARL STORZ Endoscopy-America$57EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-31KARL STORZ Endoscopy-America$24EducationIn-kind items and servicesn.a. Device, VIDEOIMAGING2021
2021-12-29PFIZER INC.$8,919Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-12-29PFIZER INC.$3,011Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-12-28PFIZER INC.$20,579Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-12-28Intercept Pharmaceuticals, Inc.$1,365Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGYRandomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)2021
2021-12-28Novo Nordisk AS$50Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-12-24PFIZER INC.$25,234Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-12-23Merck Sharp & Dohme LLC$43,274Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2021
2021-12-23Alexion Pharmaceuticals, Inc.$12,490Research paymentCash or cash equivalentA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2021
2021-12-22PFIZER INC.$6,420Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2021
2021-12-22Novo Nordisk AS$2,308Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-12-22PFIZER INC.$1,003Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-12-21Akcea Therapeutics, Inc.$6,518Research paymentCash or cash equivalentTEGSEDI Drug, NEUROLOGYIST-2019-06012021
2021-12-15Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2021
2021-12-15Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2021
2021-12-15Bio-Rad Laboratories, Inc.$591Debt forgivenessCash or cash equivalentLiquichek Device, Controls2021
2021-12-13Janssen Research & Development, LLC$18,730Research paymentCash or cash equivalentAn Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E2021
2021-12-13Janssen Research & Development, LLC$2,920Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2021
2021-12-09Takeda Pharmaceuticals U.S.A., Inc.$1,911Research paymentCash or cash equivalentENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZU2021
2021-12-09Novo Nordisk AS$25Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-12-09Novo Nordisk AS$9Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-12-08VERTEX PHARMACEUTICALS INCORPORATED$50,000GrantCash or cash equivalent2021
2021-12-08PFIZER INC.$6,998Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-12-07PFIZER INC.$33,974Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-12-07PFIZER INC.$4,029Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2021
2021-12-07PFIZER INC.$3,963Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-12-07Hoffmann-La Roche Limited$1,890Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2021
2021-12-07Rigel Pharmaceuticals, Inc.$1,625Research paymentCash or cash equivalentTavalisse Drug, HematologyO-FOSTA-9012021
2021-12-06Boston Scientific Corporation$827Research paymentCash or cash equivalentResonate Device, TachyPRECISION EVENT MONITORING OF PATIENTS WITH HF USING HEARTLO2021
2021-12-03G1 Therapeutics, Inc.$22,176Research paymentCash or cash equivalentCosela Drug, HEMATOLOGY AND ONCOLOGYG1T28-2072021
2021-12-02PFIZER INC.$11,823Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-12-02Novo Nordisk AS$25Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-12-02Novo Nordisk AS$9Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-12-01PFIZER INC.$285,600Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-12-01Novo Nordisk AS$5,277Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-12-01Laminate Medical Technologies inc.$5,167Research paymentCash or cash equivalentVasQ External Support Device, BA Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous2021
2021-12-01Hoffmann-La Roche Limited$764Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2021
2021-12-01Novo Nordisk AS$375Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-11-25PFIZER INC.$17,441Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-11-24PFIZER INC.$4,934Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-11-23PFIZER INC.$22,584Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2021
2021-11-23Abbott Laboratories$15,742Research paymentIn-kind items and servicesArchitect i2000SR Analyser System Device, Core DiagnosticsPerformance Evaluation of Architect SARS-CoV-2 IgG & IgM vs Alinity SARS-CoV-2 IgG & IgM2021
2021-11-23PFIZER INC.$13,860Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-11-18Hoffmann-La Roche Limited$2,500Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2021
2021-11-18PFIZER INC.$1,388Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-11-18Hoffmann-La Roche Limited$1,300Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2021
2021-11-18Hoffmann-La Roche Limited$1,300Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2021
2021-11-18Medline Industries LP$629Research paymentIn-kind items and servicesDRESSING, GEL FIBER, OPTICELL AG Device, Dermatology/Wound CareOpticell and Aquacel study: A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dr2021
2021-11-18Hoffmann-La Roche Limited$487Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2021
2021-11-17Organon Llc$2,358Research paymentCash or cash equivalentIMPLANON Drug, CONTRACEPTIVESA Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK2021
2021-11-16Becton, Dickinson and Company$370Charitable ContributionIn-kind items and services2021
2021-11-16Becton, Dickinson and Company$62Charitable ContributionIn-kind items and services2021
2021-11-16Becton, Dickinson and Company$55Charitable ContributionIn-kind items and services2021
2021-11-16Becton, Dickinson and Company$47Charitable ContributionIn-kind items and services2021
2021-11-15Becton, Dickinson and Company$202Charitable ContributionIn-kind items and services2021
2021-11-12Neurocrine BioSciences, Inc.$1,300Research paymentCash or cash equivalentOPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT2021
2021-11-12Neurocrine BioSciences, Inc.$1,300Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBEN2021
2021-11-11Becton, Dickinson and Company$11,047Charitable ContributionIn-kind items and services2021
2021-11-11Becton, Dickinson and Company$1,439Charitable ContributionIn-kind items and services2021
2021-11-11Becton, Dickinson and Company$191Charitable ContributionIn-kind items and services2021
2021-11-11Becton, Dickinson and Company$125Charitable ContributionIn-kind items and services2021
2021-11-10Takeda Pharmaceuticals U.S.A., Inc.$9,684Research paymentCash or cash equivalentTEDUGLUTIDE FOR TREATMENT OF SHORT BOWEL SYNDROME IN REAL WORLD SETTINGS: CENTER-BASED STUDY IN THE US AND EU2021
2021-11-10PFIZER INC.$4,571Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-11-10PFIZER INC.$1,418Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-11-10Becton, Dickinson and Company$55Charitable ContributionIn-kind items and services2021
2021-11-10Becton, Dickinson and Company$47Charitable ContributionIn-kind items and services2021
2021-11-09Becton, Dickinson and Company$45Charitable ContributionIn-kind items and services2021
2021-11-09Becton, Dickinson and Company$33Charitable ContributionIn-kind items and services2021
2021-11-09Becton, Dickinson and Company$33Charitable ContributionIn-kind items and services2021
2021-11-08Organon Llc$16,763Research paymentCash or cash equivalentIMPLANON Drug, CONTRACEPTIVES8415-8415-060-PN060-Extended Duration Study (Celanese + 2 years)-Contraception-SC-imp-Supplemental Registration-USA-LD-B2021
2021-11-08Becton, Dickinson and Company$258Charitable ContributionIn-kind items and services2021
2021-11-08Becton, Dickinson and Company$242Charitable ContributionIn-kind items and services2021
2021-11-08Becton, Dickinson and Company$201Charitable ContributionIn-kind items and services2021
2021-11-08Becton, Dickinson and Company$176Charitable ContributionIn-kind items and services2021
2021-11-08Becton, Dickinson and Company$121Charitable ContributionIn-kind items and services2021
2021-11-08Becton, Dickinson and Company$95Charitable ContributionIn-kind items and services2021
2021-11-08Becton, Dickinson and Company$55Charitable ContributionIn-kind items and services2021
2021-11-08Organon Llc$20Research paymentCash or cash equivalentIMPLANON Drug, CONTRACEPTIVESA Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK2021
2021-11-05PFIZER INC.$9,369Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-11-05PFIZER INC.$634Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2021
2021-11-04Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-11-04Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-11-03Alexion Pharmaceuticals, Inc.$489Research paymentCash or cash equivalentA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2021
2021-11-01Boston Scientific Corporation$28,887Research paymentCash or cash equivalentResonate Device, TachyPRECISION EVENT MONITORING OF PATIENTS WITH HF USING HEARTLO2021
2021-10-30PFIZER INC.$3,944Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-10-29Janssen Research & Development, LLC$476Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2021
2021-10-28ABBVIE INC.$1,879Research paymentCash or cash equivalentAn Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in P2021
2021-10-27COLOPLAST CORP$120,000Charitable ContributionCash or cash equivalentTitan Device, Men's Health2021
2021-10-27Novo Nordisk AS$6,758Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-10-27Novo Nordisk AS$3,000Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-10-27PFIZER INC.$1,388Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-10-26Takeda Pharmaceuticals U.S.A., Inc.$961Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2021
2021-10-21Hoffmann-La Roche Limited$52,826Research paymentCash or cash equivalentActemra Biological, ImmunologySAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA2021
2021-10-20Medline Industries LP$1,366Research paymentCash or cash equivalentDRESSING, GEL FIBER, OPTICELL AG Device, Dermatology/Wound CareOpticell and Aquacel study: A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dr2021
2021-10-20Organon Llc$491Research paymentCash or cash equivalentIMPLANON Drug, CONTRACEPTIVESA Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK2021
2021-10-16PFIZER INC.$2,715Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-10-16PFIZER INC.$1,269Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2021
2021-10-13Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2021
2021-10-13Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2021
2021-10-11C. R. Bard, Inc. & Subsidiaries$62,800Research paymentCash or cash equivalentArctic Sun 5000 Device, Medical SystemsINTREPID BMD11112021
2021-10-09PFIZER INC.$10,023Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-10-09PFIZER INC.$53Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-10-08PFIZER INC.$8,033Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-10-08PFIZER INC.$3,292Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2021
2021-10-05PFIZER INC.$6,170Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-10-04Bayer Healthcare Pharmaceuticals Inc.$435Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2021
2021-10-01Merck Sharp & Dohme LLC$98,893Research paymentCash or cash equivalentSTEGLATRO Drug, ENDOCRINOLOGYSTUDY NAMEEffects of SGLT2 inhibition on cardiac mitochondrial function, energetics and remodeling in non-diabetic mice 2021
2021-09-29PFIZER INC.$9,100Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-09-29Johnson & Johnson Health Care Systems Inc.$120Debt forgivenessIn-kind items and services2021
2021-09-28PFIZER INC.$285,507Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2021
2021-09-28Merck Sharp & Dohme LLC$149,226Research paymentCash or cash equivalentISENTRESS Drug, INFECTIOUS DISEASEIntensified antiretroviral therapy with raltegravir in acute HIV infection to limit establishment of the viral reservoir2021
2021-09-28Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-09-28Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-09-25PFIZER INC.$25,430Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-09-24Novo Nordisk AS$3,438Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-09-24Novo Nordisk AS$375Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-09-23ABBVIE INC.$2,171Research paymentCash or cash equivalentVENCLEXTA Drug, ONCOLOGYA Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexa2021
2021-09-22Rigel Pharmaceuticals, Inc.$3,762Research paymentCash or cash equivalentTavalisse Drug, HematologyO-FOSTA-9012021
2021-09-22Rigel Pharmaceuticals, Inc.$1,625Research paymentCash or cash equivalentTavalisse Drug, HematologyO-FOSTA-9012021
2021-09-22Rigel Pharmaceuticals, Inc.$1,625Research paymentCash or cash equivalentTavalisse Drug, HematologyO-FOSTA-9012021
2021-09-22Rigel Pharmaceuticals, Inc.$1,625Research paymentCash or cash equivalentTavalisse Drug, HematologyO-FOSTA-9012021
2021-09-22Rigel Pharmaceuticals, Inc.$1,625Research paymentCash or cash equivalentTavalisse Drug, HematologyO-FOSTA-9012021
2021-09-22PFIZER INC.$1,572Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2021
2021-09-22PFIZER INC.$944Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-09-21PFIZER INC.$6,440Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-09-21ABBVIE INC.$2,427Research paymentCash or cash equivalentAn Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in P2021
2021-09-15PFIZER INC.$9,504Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2021
2021-09-14PFIZER INC.$8,674Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-09-08PFIZER INC.$8,596Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-09-04PFIZER INC.$6,948Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-09-04PFIZER INC.$2,510Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2021
2021-09-03Novo Nordisk AS$23Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-09-03Novo Nordisk AS$5Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-09-03Johnson & Johnson Health Care Systems Inc.$0Debt forgivenessIn-kind items and services2021
2021-09-02Celgene Corporation$4,986Research paymentCash or cash equivalentA Phase 3, Multicenter, Open-Label Extension Trial2021
2021-09-01Novo Nordisk AS$69Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-31PFIZER INC.$4,551Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-08-31Becton, Dickinson and Company$64Charitable ContributionIn-kind items and services2021
2021-08-30Janssen Research & Development, LLC$635Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2021
2021-08-27Abbott Laboratories$31,484Research paymentIn-kind items and servicesArchitect i2000SR Analyser System Device, Core DiagnosticsPerformance Evaluation of Architect SARS-CoV-2 IgG & IgM vs Alinity SARS-CoV-2 IgG & IgM2021
2021-08-27PFIZER INC.$27,271Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2021
2021-08-26Janssen Research & Development, LLC$765Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo2021
2021-08-25Novo Nordisk AS$3,374Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522021
2021-08-25G1 Therapeutics, Inc.$2,609Research paymentCash or cash equivalentCosela Drug, HEMATOLOGY AND ONCOLOGYG1T28-2072021
2021-08-25Alexion Pharmaceuticals, Inc.$1,793Research paymentCash or cash equivalentA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2021
2021-08-24PFIZER INC.$1,875Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN2021
2021-08-24PFIZER INC.$709Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2021
2021-08-21PFIZER INC.$47,304Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2021
2021-08-21PFIZER INC.$5,675Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021
2021-08-20Novo Nordisk AS$56Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522021

The latest 200 records of 469.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In Massachusetts; placed by its state only.

MeasureState
Massachusetts
Population B010037,044,056
Population, 2020 census P17,029,917
Median age B0100240.0
Under 18 B0100119.4%
65 and over B0100117.9%
Households B110012,785,042
Foreign born B0500218.0%
Median household income B19013$103,960
Median family income B19113$131,675
Per capita income B19301$57,897
Poverty rate B1700110.0%
Unemployment rate B230255.2%
Civilian labor force B230253,911,446
Mean commute (minutes) B0801329.1
Bachelor's degree or higher B1500347.3%
Housing units B250013,030,406
Owner-occupied B2500362.5%
Renters B2500337.5%
Median home value B25077$562,100
Median gross rent B25064$1,762
White, not Hispanic B0300266.6%
Black B030026.4%
Hispanic or Latino B0300213.3%
Asian B030027.3%
American Indian and Alaska Native B030020.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.